Lower incidence of hepatocellular carcinoma with tenofovir alafenamide in chronic hepatitis B: Evidence from a large-scale cohort

Lower incidence of hepatocellular carcinoma with tenofovir alafenamide in chronic hepatitis B: Evidence from a large-scale cohort

Background & Aims: Tenofovir alafenamide (TAF) lacks extensive research regarding its impact on hepatocellular carcinoma (HCC). This study evaluated and compared the effects of TAF, tenofovir disoproxil fumarate (TDF), and entecavir (ETV) on HCC incidence using nationwide claim data. Methods...

Full description

Saved in:
Bibliographic Details
Main Authors: Hye-Jin Yoo, Jae-Young Kim, Jeong-Ju Yoo, Hye Won Lee, Sang Gyune Kim, Young Seok Kim
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:JHEP Reports
Subjects:
Antiviral therapy
Chronic HBV
Cirrhosis
Healthcare data analysis
Comparative efficacy
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555924002726
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items